Workflow
Bionano Genomics(BNGO)
icon
Search documents
Bionano Announces the Final Speaker Lineup for 2024 Symposium with 33 OGM Presentations and Live Panel Discussions Across a Wide Range of Research Applications
Newsfilter· 2024-01-19 13:00
26 different customers representing North America, Asia and Europe33 oral presentations across four consecutive days69 scientific posters will be featured in a virtual exhibition hallTopics span the application of optical genome mapping (OGM) in research applications in cancer, cell and gene therapy, and genetic diseases SAN DIEGO, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc (NASDAQ:BNGO) today announced its 2024 Symposium lineup of 33 oral presentations delivered by 26 different customers world ...
Contrarian Kings: 3 Unloved Stocks That Could Be the Next Market Darlings
InvestorPlace· 2024-01-17 10:53
On Wall Street zeroes can become heroes relatively quickly. For example, in the past the Street hated Roku (NASDAQ:ROKU), Intel (NASDAQ:INTC), Shopify (NYSE:SHOP) and Pinterest (NYSE:PINS) and now they’re all among the most beloved names in the stock market. Often, positive macro trends can explain the transformation. For example, Roku and Pinterest got a big boost due to the acceleration of advertising spending. Obviously, investors can make a great deal of money by correctly predict which names will go fr ...
Bionano Announces Peer-Reviewed Publication from its Clinical Study Designed to Support OGM as Part of Standard of Care (SOC) in Genetic Disease Testing
Newsfilter· 2024-01-11 21:01
Peer-reviewed publication from Broeckel, et al. describes the second phase of a multisite evaluation of optical genome mapping (OGM) in 627 samples (597 unique samples and 30 replicates)Overall, for the entire study, OGM data have been collected from 1,000 samples, including 404 samples from phase 1 of the studyConcordance for pathogenic variants in all combined samples against standard of care (SOC) methods – 99.5% (995 out of 1,000 samples)When compared to the rate of finding pathogenic or likely pathogen ...
Bionano Announces 2024 Symposium: Four Consecutive Days of OGM Presentations and Live Panel Discussions Across a Wide Range of Research Applications
Newsfilter· 2024-01-10 13:00
SAN DIEGO, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced its 2024 Symposium, the quintessential event for the optical genome mapping (OGM) community. The event is an opportunity for OGM users to present their progress to the world. 2024 Symposium will feature four consecutive days of OGM presentations delivered by 27 different customers worldwide across a wide range of applications in cancer, cell and gene therapy, and constitutional genetic disease. The Symposium wi ...
OGM Added to International System for Human Cytogenomic Nomenclature
Newsfilter· 2024-01-03 13:00
SAN DIEGO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO), today announced a publication outlining the addition of optical genome mapping (OGM) to the International System for Human Cytogenomic Nomenclature (ISCN). The OGM nomenclature is expected to be published in the 2024 edition of the ISCN guide, a reference volume covering ISCN nomenclature that is utilized worldwide by cytogeneticists, molecular biologists, technicians, and students. ISCN nomenclature is an international stand ...
Bionano Announces Significant Upgrades to its Bionano Solve Pipeline and its VIA™ Software for OGM Data Analysis in Constitutional Genetic Disease Research
Newsfilter· 2023-12-28 13:00
SAN DIEGO, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO), today announced significant upgrades to its pipeline for analysis of optical genome mapping (OGM) data in its VIA™ software for applications in constitutional genetic disease. The latest analysis pipeline, Bionano Solve 3.8.1, enhances the sensitivity and specificity for structural variation (SV) detection from OGM data, which, when combined with copy number variant (CNV) analysis capabilities introduced in July 2023, further ...
Bionano Announces Publication of Largest Prospective Prenatal Study Comparing OGM to Chromosomal Microarray Analysis and Karyotyping
Newsfilter· 2023-12-26 13:00
Key findings from prospective evaluation of 200 prenatal samples: Optical genome mapping (OGM) detected pathogenic structural variants (SVs) in 20.5% of samples (41/200); combination of chromosomal microarray analysis (CMA) and karyotyping (KT) detected pathogenic SVs in 19.5% of samples (39/200)Compared to CMA and KT combined in this prospective cohort, OGM had the following performance: Sensitivity: 97.4%Specificity: 100%Positive Predictive Value (PPV): 100%Negative Predictive Value (NPV): 99.4% For 8 co ...
Bionano Genomics, Inc. (BNGO) Presents at Stifel Healthcare Conference (Transcript)
2023-11-15 20:23
Bionano Genomics, Inc. (NASDAQ:BNGO) Stifel Healthcare Conference Call November 15, 2023 1:50 PM ET Company Participants Erik Holmlin - CEO Conference Call Participants Dan Arias - Stifel Dan Arias Okay. Welcome back to the 2023 Stifel Healthcare Conference Day Two. We are on the life sciences and diagnostics track here. I am Dan Arias. I’m the life sciences and diagnostics analyst. We’re happy to have with us our next company, Bionano Genomics. CEO, Erik Holmlin is with us. I think, Erik, maybe you’re goin ...
Bionano Genomics(BNGO) - 2023 Q3 - Earnings Call Transcript
2023-11-08 23:58
Bionano Genomics, Inc. (NASDAQ:BNGO) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants David Holmes - Investor Relations Erik Holmlin - Chief Executive Officer Gülsen Kama - Chief Financial Officer Conference Call Participants Michael Okunewitch - Maxim Group Sung Ji Nam - Scotiabank Jeffrey Cohen - Ladenburg Thalmann Operator Good day, and welcome to the Bionano's Third Quarter 2023 Earnings Conference Call. Today's conference is being recorded. At this time, I would like to ...
Bionano Genomics(BNGO) - 2023 Q3 - Quarterly Report
2023-11-07 16:00
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-38613 _________________________________________________________ Bionano Genomics, Inc. (Exact name of registrant as specified in its charter) Securities registered pursuant to Section 12(b) of the Act: Indicate by check ...